VIENNA—Latest research on breast cancer prevention was reported at the 20125 St Gallen breast cancer conference in a session concluded by Jack Cuzick, PhD, Director of the Wolfson Institute of Preventive Medicine and Head of the Centre for Cancer Prevention at Queen Mary, University of London. Oncology Times reporter Sarah Maxwell began by asking him about the IBIS I and II studies—using drugs affecting the estrogen receptor—and about IBIS III using aromatase inhibitor, bisphosphonate and metformin for primary prevention.
Preventing ER-Positive Breast Cancer—Latest from IBIS 1, 2 and 3
Further reading
The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell...
Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant...
Babies Use Object Permanence To Get What They Want 2022: A report from the journal: Pediatric Physical Therapy Regina Harbourne PhD, PT, PCS, FAPTA...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...